162 related articles for article (PubMed ID: 36193074)
1.
Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y
Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074
[TBL] [Abstract][Full Text] [Related]
2. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
3. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
4. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
6. TTC7B is a new prognostic biomarker in head and neck squamous cell carcinoma linked to immune infiltration and ferroptosis.
He R; Zhang X; Wu Y; Weng Z; Li L
Cancer Med; 2023 Dec; 12(24):22354-22369. PubMed ID: 37990988
[TBL] [Abstract][Full Text] [Related]
7. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.
Xu J; Liu F; Li Y; Shen L
Cell Mol Neurobiol; 2022 Apr; 42(3):709-722. PubMed ID: 32894375
[TBL] [Abstract][Full Text] [Related]
8. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
[TBL] [Abstract][Full Text] [Related]
9. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
10. FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide.
Zhou K; Jiang T; Liu Y; Zhao Z; Huang L; Li G
BMC Neurol; 2021 Nov; 21(1):438. PubMed ID: 34753441
[TBL] [Abstract][Full Text] [Related]
11. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
12. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
14. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
16. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
[TBL] [Abstract][Full Text] [Related]
17. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
18. The N6-Methylandenosine-Related Gene
Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
[TBL] [Abstract][Full Text] [Related]
19. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
